Mast Therapeutics (NYSEMKT:MSTX): $0.02 million was the positive money flow into the stock on Wednesday and the up/down ratio of ticks was also in favor of the bulls at 2.83. The value of trades done on upticks was $0.03 million, whereas, trades done on downticks were valued at $0.01 million. Money flows are calculated as the dollar value of composite uptick trades minus the dollar value of downtick trades. large traders, also sometimes called as the smart money, block traded $0.02 million worth stocks on upticks, which is a bullish indication. The money flow in block trades was $0.02 million. Mast Therapeutics (NYSEMKT:MSTX) fell $0 traded at $0.47, a change of -0.38% over the previous day. The stock is 4.58% for the week.
In an insider trading activity, Roberts Brandi, CFO of Mast Therapeutics, Inc., executed a transaction worth $19,000 on March 26, 2015. A total of 38,000 shares were purchased at an average price of $0.5. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered. Currently the company Insiders own 4.26% of Mast Therapeutics shares according to the proxy statements. Institutional Investors own 13.87% of Mast Therapeutics shares.
The company shares have dropped -4.08% from its 1 Year high price. On Sep 30, 2015, the shares registered one year high at $0.60 and the one year low was seen on Feb 10, 2016. The 50-Day Moving Average price is $0.38 and the 200 Day Moving Average price is recorded at $0.35. Mast Therapeutics (NYSEMKT:MSTX): The stock opened at $0.48 on Wednesday but the bulls could not build on the opening and the stock topped out at $0.48 for the day. The stock traded down to $0.46 during the day, due to lack of any buying support eventually closed down at $0.46 with a loss of -2.54% for the day. The stock had closed at $0.47 on the previous day. The total traded volume was 3,097,645 shares.
Mast Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops therapies for serious or life-threatening diseases with unmet needs. The Company leverages its Molecular Adhesion and Sealant Technology (MAST) platform, to develop MST-188 (vepoloxamer) Injection, the Companys lead product candidate. Vepoloxamer is being tested in a Phase III clinical study called EPIC for the treatment of vaso-occlusive crisis in patients with sickle cell disease. The Company also develops AIR001, a sodium nitrite solution for intermittent inhalation through nebulizer. AIR001 is being tested in multiple institution-sponsored Phase IIa clinical studies that provide the Company with data on AIR001s potential to treat patients with preserved ejection fraction (HFpEF).